A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti−PD1 Antibody) Compared With Docetaxel in Patients With Non−Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Tislelizumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors BeiGene
- 13 Nov 2017 According to a BeiGene media release, the company has initiated the trial for treatment of patients with advanced lung cancer.
- 13 Nov 2017 Status changed from planning to recruiting, according to a BeiGene media release.
- 03 Oct 2017 New trial record